A Comprehensive Assessment of Liver Transplant Trends and Outcomes Among Adults With Steatotic Liver Disease in the U.S

Overview

Journal Gastro Hep Adv

Specialty Gastroenterology

Date 2025 Mar 3

PMID 40026700

Authors

Shyam Patel

Sohil Patel

Wei Zhang

Ashwani K Singal

Ramsey Cheung

Robert J Wong

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Steatotic liver disease (SLD) is the leading indication for liver transplantation (LT) among U.S. adults. We aim to provide comprehensive updates of LT trends and outcomes among adults with SLD, highlighting racial, ethnic, and sociodemographic disparities.

Methods: Using data from the 2010 to 2023 United Network for Organ Sharing registry, we performed a retrospective cohort study evaluating LT waitlist trends, waitlist outcomes, and post-LT survival among 65,675 adults with SLD. Disparities in LT outcomes were evaluated using adjusted competing risks analyses.

Results: From 2014 to 2023, there was an increasing proportion of Hispanics, women, and younger adults with SLD listed for LT. For Hispanics, this was driven by metabolic dysfunction-associated steatohepatitis (MASH); 19.9% of MASH wait-listings in 2023 were Hispanics. For women and younger adults (18-39 years), this was driven by alcohol-associated liver disease (ALD); 30.9% and 16.4% of ALD-related wait-listings in 2023 were women and younger adults, respectively. Women (vs men) had greater waitlist removal risk (subdistribution hazard ratio (sHR) 1.12, 95% confidence interval (CI) 1.07-1.18) and lower likelihood of LT receipt (sHR 0.87, 95% CI, 0.85-0.90). Ethnic minorities had worse outcomes, particularly Hispanics, who had a 37% higher risk of waitlist removal (sHR 1.37, 95% CI, 1.30-1.45) and 16% lower likelihood of LT receipt (sHR 0.86, 95% CI, 0.82-0.87) vs non-Hispanic whites. Disparities in post-LT survival were also observed.

Conclusion: In 2023, nearly one-quarter of MASH liver transplant waitlist registrants were Hispanics. Approximately half and 1 in 6 ALD waitlist registrants were women and younger adults, respectively. These concerning trends are amplified by the disparities in LT outcomes observed among women and ethnic minorities.

References

Wong R, Singal A . Trends in Liver Disease Etiology Among Adults Awaiting Liver Transplantation in the United States, 2014-2019. JAMA Netw Open. 2020; 3(2):e1920294. DOI: 10.1001/jamanetworkopen.2019.20294. View

Allen A, Heimbach J, Larson J, Mara K, Kim W, Kamath P . Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation. Transplantation. 2018; 102(10):1710-1716. PMC: 6153066. DOI: 10.1097/TP.0000000000002196. View

Fabbrini E, Sullivan S, Klein S . Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2009; 51(2):679-89. PMC: 3575093. DOI: 10.1002/hep.23280. View

Balakrishnan M, Kanwal F, El-Serag H, Thrift A . Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings From the National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 2016; 15(2):310-312. PMC: 5241175. DOI: 10.1016/j.cgh.2016.09.149. View

Yalamanchili K, Saadeh S, Klintmalm G, Jennings L, Davis G . Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl. 2010; 16(4):431-9. DOI: 10.1002/lt.22004. View

Fryar C, Kruszon-Moran D, Gu Q, Ogden C . Mean Body Weight, Height, Waist Circumference, and Body Mass Index Among Adults: United States, 1999-2000 Through 2015-2016. Natl Health Stat Report. 2019; (122):1-16. View

Nephew L, Mosesso K, Desai A, Ghabril M, Orman E, Patidar K . Association of State Medicaid Expansion With Racial/Ethnic Disparities in Liver Transplant Wait-listing in the United States. JAMA Netw Open. 2020; 3(10):e2019869. PMC: 7545310. DOI: 10.1001/jamanetworkopen.2020.19869. View

Shuey B, Halbisen A, Lakoma M, Zhang F, Argetsinger S, Williams E . High-Acuity Alcohol-Related Complications During the COVID-19 Pandemic. JAMA Health Forum. 2024; 5(4):e240501. PMC: 11065164. DOI: 10.1001/jamahealthforum.2024.0501. View

Ochoa-Allemant P, Marrero J, Serper M . Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States. Hepatol Commun. 2023; 7(12). PMC: 10697602. DOI: 10.1097/HC9.0000000000000324. View

10.

Mathur A, Ashby V, Fuller D, Zhang M, Merion R, Leichtman A . Variation in access to the liver transplant waiting list in the United States. Transplantation. 2014; 98(1):94-9. PMC: 4211283. DOI: 10.1097/01.TP.0000443223.89831.85. View

11.

Julien J, Ayer T, Bethea E, Tapper E, Chhatwal J . Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study. Lancet Public Health. 2020; 5(6):e316-e323. DOI: 10.1016/S2468-2667(20)30062-1. View

12.

Ross K, Patzer R, Goldberg D, Lynch R . Sociodemographic Determinants of Waitlist and Posttransplant Survival Among End-Stage Liver Disease Patients. Am J Transplant. 2017; 17(11):2879-2889. DOI: 10.1111/ajt.14421. View

13.

Turse E, Aboona M, Charley E, Forlemu A, Bowie T, Bhattarai B . Factors Associated with Survival of Hepatocellular Carcinoma (HCC) Patients at a Safety Net Hospital in Arizona without On-Site Liver Transplant Program. J Hepatocell Carcinoma. 2022; 9:1-11. PMC: 8791297. DOI: 10.2147/JHC.S341690. View

14.

Lee B, Dodge J, Terrault N . National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology. 2023; 79(3):666-673. PMC: 11232657. DOI: 10.1097/HEP.0000000000000604. View

15.

Kim W, Mannalithara A, Heimbach J, Kamath P, Asrani S, Biggins S . MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021; 161(6):1887-1895.e4. PMC: 8608337. DOI: 10.1053/j.gastro.2021.08.050. View

16.

Pollard M, Tucker J, Green Jr H . Changes in Adult Alcohol Use and Consequences During the COVID-19 Pandemic in the US. JAMA Netw Open. 2020; 3(9):e2022942. PMC: 7525354. DOI: 10.1001/jamanetworkopen.2020.22942. View

17.

Rinella M, Lazarus J, Ratziu V, Francque S, Sanyal A, Kanwal F . A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023; 78(6):1966-1986. PMC: 10653297. DOI: 10.1097/HEP.0000000000000520. View

18.

Yilma M, Kim N, Shui A, Tana M, Landis C, Chen A . Factors Associated With Liver Transplant Referral Among Patients With Cirrhosis at Multiple Safety-Net Hospitals. JAMA Netw Open. 2023; 6(6):e2317549. PMC: 10251211. DOI: 10.1001/jamanetworkopen.2023.17549. View

19.

Younossi Z, Stepanova M, Sanyal A, Harrison S, Ratziu V, Abdelmalek M . The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. J Hepatol. 2018; 69(6):1365-1370. DOI: 10.1016/j.jhep.2018.08.013. View

20.

Wilder J, Oloruntoba O, Muir A, Moylan C . Role of patient factors, preferences, and distrust in health care and access to liver transplantation and organ donation. Liver Transpl. 2016; 22(7):895-905. PMC: 5567682. DOI: 10.1002/lt.24452. View